Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of T Cell Receptor Gene Therapy Targeting Human Papillomavirus ( HPV) 16 E7 for HPV-Associated Cancers

NCT05686226 is registered in ClinicalTrials.gov with Christian Hinrichs as lead sponsor.

NCT NCT05686226
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05686226 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of T Cell Receptor Gene Therapy Targeting Human Papillomavirus ( HPV) 16 E7 for HPV-Associated Cancers
Lead sponsor
Christian Hinrichs
Phase
Phase 2
Overall status
Recruiting
Start date
March 7, 2023
Completion date
January 1, 2027
Enrollment
20 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

anal cancer, cervical cancer, hpv positive oropharyngeal squamous cell carcinoma, hpv positive rectal squamous cell carcinoma, hpv-associated vaginal adenocarcinoma, hpv-related adenocarcinoma, hpv-related adenosquamous carcinoma, hpv-related anal squamous cell carcinoma, hpv-related carcinoma, hpv-related cervical carcinoma, hpv-related endocervical adenocarcinoma, hpv-related malignancy, hpv-related penile squamous cell carcinoma, hpv-related squamous cell carcinoma, hpv-related vulvar squamous cell carcinoma, metastatic cancer, oropharynx cancer, penile cancer, throat cancer, vaginal cancer, vulva cancer